<scp>YM155</scp> down‐regulates survivin and <scp>XIAP</scp>, modulates autophagy and induces autophagy‐dependent <scp>DNA</scp> damage in breast cancer cells

Abstract

YM155 is a potent survivin inhibitor that has potential for the management of various breast cancer subtypes regardless of the expression of ER, HER2 and caspase-3. Importantly, this study provides new insights into YM155's molecular mechanism of action and therapeutic potential in the treatment of tamoxifen-resistant breast cancer.